TNF and pancreatic serous cystadenoma: Meanwhile, Kulkarni et al16 found that PSC-IBD patients receiving anti-TNFα therapy had a more than 3-fold odds of developing bacterial cholangitis (OR 3.45, 95% CI, 1.54-7.76), with 50% of patients developing cholangitis within 36 months of starting therapy.